secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0000950170-23-053894
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel announces Nature publication: CAN-3110 extends survival in recurrent high-grade glioma
--------------------------------------------------------------------------------

- Phase 1 trial (n=41) of CAN-3110 in recurrent HGG showed median OS of 11.6 months, nearly double historical 6-9 months.
- HSV-1 seropositive patients had median OS 14.2 months vs 7.8 months for seronegative; seroconversion linked to improved survival.
- Treatment well tolerated with no dose-limiting toxicity; increased immune cell infiltration and T-cell repertoire diversity observed.
- Arm C will evaluate up to six injections of CAN-3110, supported by Break Through Cancer foundation.
- Publication in Nature titled 'Clinical trial links oncolytic immunoactivation to survival in glioblastoma'.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023053894/0000950170-23-053894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023053894/cadl-20231018.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer